🫀 Oral semaglutide reduces heart failure events in T2D: SOUL secondary analysis

🧪 Large secondary analysis from SOUL trial (n = 9,650), randomized T2D patients with atherosclerotic CVD and/or CKD to oral semaglutide vs placebo; median follow-up 47.5 months. Subgroup analysis by HF history (including HFpEF and HFrEF).

📈 For participants with baseline HF, oral semaglutide reduced risk of composite HF outcome (HR = 0.78, 95%CI 0.63–0.96). Greatest benefit seen in HFpEF (HR = 0.59, 95%CI 0.39–0.86); not significant in HFrEF (HR = 0.98). No excess in serious adverse events. MACE reduction consistent regardless of HF status.

📍 Consider oral semaglutide to reduce HF events, especially in T2D patients with HFpEF or at high cardiovascular/renal risk. No safety compromise observed.

🔗 PubMed | DOI

✅ Oral semaglutide: significant gains in QoL, metabolic outcomes, and tolerability

🧪 Prospective multicenter observational cohort (Galicia, Spain; n = 43 T2D) assessed oral semaglutide effects over 3–6 months—validated QoL instruments (DTSQ, EuroQol), anthropometrics, metabolic panel, and adverse events.

📈 Marked improvement in visual analog QoL scale (+9.8 points) and DTSQ (+4.8), both p < 0.001; HbA1c fell from 8.3% to 7.2% (p < 0.001), weight -4.9% (p = 0.018). Nausea/vomiting in 39.5%, but no observed detriment to QoL.

📍 Initiating oral semaglutide can meaningfully enhance patient-reported outcomes and glycemic control; anticipate/titrate for GI AEs, but discontinuations were rare.

🔗 PubMed | DOI

⚠️ Imaging-based safety signal: multi-organ side effects after single semaglutide dose

🧪 Case report: 60F, metastatic breast cancer, developed marked PET/CT evidence of gastric retention, gallbladder, colonic, and renal uptake—suggestive of gastroparesis, cholecystitis, colitis, and AKI—within 5 days of first-ever semaglutide injection. Symptoms and findings resolved after drug cessation.

📊 Not previously visualized on imaging after a single semaglutide dose; clinical correlation confirmed organ involvement.

📍 Remain alert to the potential for multi-organ (GI/biliary/renal) sequelae even at first-dose, particularly in patients with additional risk factors; supportive care and timely discontinuation reversed findings.

🔗 PubMed | DOI

✅ Oral semaglutide improves MetS components in T2D with hypothyroidism

🧪 Retrospective cohort (n=51) with T2D & hypothyroidism on oral semaglutide (14 mg/d, 6 months) assessed HbA1c, BMI, BP, and lipids.

📈 HbA1c reduced by 6.7% (p<0.001), BMI by 4.04% (p<0.001), triglycerides by 6.7% (p<0.001), HDL-C up 9% (p=0.002).

📍 Oral semaglutide is reasonable for patients with both T2D and hypothyroidism, improving key cardiometabolic parameters. Monitor for possible levothyroxine dose adjustments.

🔗 PubMed | DOI

⚠️ First report: DVT in adolescent after oral semaglutide started off-label for weight loss

🧪 16M overweight, sedentary, developed acute lower extremity DVT within 2 weeks of starting Rybelsus (7mg QD, unsupervised). No hereditary thrombophilia; symptoms reversed with anticoagulation.

📊 Possible mechanisms: hemoconcentration from GI side effects, sedentary behavior, unknown effects on coagulation. Prior sporadic reports with injectable semaglutide/GLP-1 RAs; first with oral semaglutide.

📍 Exercise vigilance in off-label/unsupervised use, especially in adolescents; screen for risk factors, counsel on hydration and early symptoms. Further pharmacovigilance studies needed.

🔗 PubMed | DOI

🩸 Semaglutide reduces thyroid eye disease (TED) risk in T2D with autoimmune thyroiditis

🧪 Large US real-world cohort (n = 46,558; 1:1 propensity-matched; mean age 60.1; 75% female); semaglutide vs. non-GLP-1 antihyperglycemic agents. Outcomes at 5 years included TED-related diagnoses and interventions.

📈 Semaglutide users had lower TED risk vs controls (2.16% vs 2.82%; RR 0.76); also less corticosteroid use, surgical, and radiation interventions.

📍 Consider semaglutide in T2D patients with autoimmune thyroiditis, particularly those at risk for TED. Effect is associative, not necessarily causal; more research warranted.

🔗 PubMed | DOI

🛡️ Check before elective surgery: perioperative aspiration risk on semaglutide

🧪 Prospective multicenter matched-control study (n = 88) in patients fasted pre-op; 44 on semaglutide, 44 controls (matched by age, BMI, DM). Gastric ultrasound: “full stomach” if solid stomach content or gastric volume >1.5 ml/kg.

📊 Full stomach in 49% of semaglutide users vs 18% of controls (OR 4.29). Solid content especially frequent in semaglutide group.

📍 Withhold semaglutide pre-op and consider point-of-care gastric ultrasound in surgical patients—even after one skipped dose. Individualize fasting instructions and perioperative anesthesia planning.

🔗 PubMed | DOI